Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACTUNYSE:ATNMNASDAQ:AVTENASDAQ:DRUG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$10.65-1.3%$8.74$5.51▼$11.73$208.95MN/A47,790 shs16,568 shsATNMActinium Pharmaceuticals$1.60-0.1%$1.46$1.03▼$8.64$50.07M-0.24498,649 shs31,583 shsAVTEAerovate Therapeutics$7.25-1.6%$54.69$43.75▼$884.98$210.14M0.9518,713 shs504,908 shsDRUGBright Minds Biosciences$27.40+0.2%$31.91$0.93▼$79.02$193.01M-5.32821,608 shs3,371 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics+4.66%-1.73%+19.23%+55.70%+1,078,999,900.00%ATNMActinium Pharmaceuticals-3.03%-6.43%+23.08%+45.45%-83.67%AVTEAerovate Therapeutics+4.84%-4.47%-92.14%-91.30%-98.69%DRUGBright Minds Biosciences-0.33%-10.12%-15.01%-19.30%+2,066.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACTUActuate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AATNMActinium Pharmaceuticals1.3938 of 5 stars3.40.00.00.01.60.00.6AVTEAerovate Therapeutics0.9717 of 5 stars3.00.00.00.00.61.70.6DRUGBright Minds Biosciences3.1019 of 5 stars3.65.00.00.02.62.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACTUActuate Therapeutics 3.00Buy$20.5092.49% UpsideATNMActinium Pharmaceuticals 2.75Moderate Buy$4.00150.31% UpsideAVTEAerovate Therapeutics 2.00Hold$78.75986.21% UpsideDRUGBright Minds Biosciences 3.25Buy$83.25203.83% UpsideCurrent Analyst Ratings BreakdownLatest ATNM, DRUG, AVTE, and ACTU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025DRUGBright Minds BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/13/2025DRUGBright Minds BiosciencesCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/13/2025DRUGBright Minds BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025DRUGBright Minds BiosciencesTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/12/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.005/7/2025DRUGBright Minds BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.004/28/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/22/2025ACTUActuate TherapeuticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.004/1/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/25/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/18/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACTUActuate TherapeuticsN/AN/AN/AN/AN/AN/AATNMActinium Pharmaceuticals$81K615.45N/AN/A$1.31 per share1.22AVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/ADRUGBright Minds BiosciencesN/AN/AN/AN/A$5.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACTUActuate Therapeutics-$24.75MN/A0.00∞N/AN/AN/AN/AN/AATNMActinium Pharmaceuticals-$48.82M-$1.39N/AN/AN/AN/A-100.85%-47.89%N/AAVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%8/11/2025 (Estimated)DRUGBright Minds Biosciences-$2.06M-$0.36N/AN/AN/AN/A-5.85%-5.68%8/13/2025 (Estimated)Latest ATNM, DRUG, AVTE, and ACTU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ACTUActuate Therapeutics-$0.26-$0.32-$0.06-$0.32N/AN/A5/15/2025Q2 2025DRUGBright Minds Biosciences-$0.39-$0.29+$0.10-$0.29N/AN/A4/25/2025Q4 2024AVTEAerovate Therapeutics-$10.50-$3.15+$7.35-$0.09N/AN/A3/27/2025Q4 2024AVTEAerovate Therapeutics-$6.65-$6.65N/A-$0.19N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACTUActuate TherapeuticsN/AN/AN/AN/AN/AATNMActinium PharmaceuticalsN/AN/AN/AN/AN/AAVTEAerovate TherapeuticsN/AN/AN/AN/AN/ADRUGBright Minds BiosciencesN/AN/AN/AN/AN/ALatest ATNM, DRUG, AVTE, and ACTU DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/9/2025AVTEAerovate Therapeutics$84.004/29/20254/25/20254/28/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACTUActuate TherapeuticsN/A1.681.68ATNMActinium PharmaceuticalsN/A10.2510.25AVTEAerovate TherapeuticsN/A8.788.78DRUGBright Minds BiosciencesN/A126.0111.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACTUActuate TherapeuticsN/AATNMActinium Pharmaceuticals27.50%AVTEAerovate TherapeuticsN/ADRUGBright Minds Biosciences40.52%Insider OwnershipCompanyInsider OwnershipACTUActuate Therapeutics69.34%ATNMActinium Pharmaceuticals6.00%AVTEAerovate Therapeutics24.90%DRUGBright Minds Biosciences42.66%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACTUActuate Therapeutics1019.62 millionN/AN/AATNMActinium Pharmaceuticals3031.20 million29.32 millionOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableDRUGBright Minds BiosciencesN/A7.04 million4.04 millionNot OptionableATNM, DRUG, AVTE, and ACTU HeadlinesRecent News About These CompaniesBright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare ConferenceMay 28 at 8:48 AM | finance.yahoo.comWhat is Chardan Capital's Forecast for DRUG FY2025 Earnings?May 27 at 1:50 AM | marketbeat.comHC Wainwright Issues Pessimistic Outlook for DRUG EarningsMay 27 at 1:35 AM | marketbeat.comHC Wainwright Has Bearish Forecast for DRUG Q3 EarningsMay 26 at 1:36 AM | americanbankingnews.comBright Minds Biosciences (NASDAQ:DRUG) Downgraded to "Sell" Rating by Wall Street ZenMay 25, 2025 | americanbankingnews.comBright Minds Biosciences (NASDAQ:DRUG) Cut to "Sell" at Wall Street ZenMay 24, 2025 | marketbeat.comChardan Capital Reiterates Buy Rating for Bright Minds Biosciences (NASDAQ:DRUG)May 23, 2025 | marketbeat.comBright Minds Biosciences (NASDAQ:DRUG) Earns "Buy" Rating from Chardan CapitalMay 23, 2025 | americanbankingnews.comPoint72 Asset Management L.P. Buys Shares of 135,189 Bright Minds Biosciences Inc. (NASDAQ:DRUG)May 22, 2025 | marketbeat.comBright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025May 20, 2025 | globenewswire.comJanus Henderson Group PLC Buys New Position in Bright Minds Biosciences Inc. (NASDAQ:DRUG)May 18, 2025 | marketbeat.comBright Minds Biosciences (NASDAQ:DRUG) Upgraded to Strong-Buy at Cantor FitzgeraldMay 17, 2025 | marketbeat.comBright Minds Biosciences (DRUG) to Release Earnings on WednesdayMay 16, 2025 | marketbeat.comTD Cowen Begins Coverage on Bright Minds Biosciences (NASDAQ:DRUG)May 15, 2025 | marketbeat.comTD Cowen Initiates Coverage of Bright Minds Biosciences (DRUG) with Buy RecommendationMay 14, 2025 | msn.comBright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101May 14, 2025 | finance.yahoo.comChardan Capital Initiates a Buy Rating on Bright Minds Biosciences (DRUG)May 9, 2025 | theglobeandmail.comBright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Rating of "Buy" from BrokeragesMay 9, 2025 | marketbeat.comChardan Capital Begins Coverage on Bright Minds Biosciences (NASDAQ:DRUG)May 9, 2025 | marketbeat.comEpilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock UpsideMay 7, 2025 | benzinga.comChardan Capital Initiates Coverage of Bright Minds Biosciences (DRUG) with Buy RecommendationMay 7, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueEli Lilly : A Breakout Biotech Powerhouse With Room to RunBy Jeffrey Neal Johnson | May 29, 2025View Eli Lilly : A Breakout Biotech Powerhouse With Room to RunATNM, DRUG, AVTE, and ACTU Company DescriptionsActuate Therapeutics NASDAQ:ACTU$10.65 -0.14 (-1.30%) As of 11:56 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.Actinium Pharmaceuticals NYSE:ATNM$1.60 0.00 (-0.13%) As of 11:59 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.Aerovate Therapeutics NASDAQ:AVTE$7.25 -0.12 (-1.63%) As of 05/28/2025Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Bright Minds Biosciences NASDAQ:DRUG$27.40 +0.05 (+0.18%) As of 11:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? CrowdStrike Stock Slips: Analyst Downgrades Before Earnings AutoZone Stock to Cross $4400 This Year: This Is Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
